Atazanavir found to help improve lipid profile. IDSA study offers good news for HIV care.
A new protease inhibitor called atazanavir actually was found to improve the lipid profile of HIV patients in a 48-week study. The study compared the total cholesterol from baseline and at 48 weeks following treatment with atazanavir.